MeSH

Compliance by health personnel or proxies with the stipulations of ADVANCE DIRECTIVES (or similar directives such as RESUSCITATION ORDERS) when patients are unable to direct their own care.

Year introduced: 2002

Conformity in fulfilling or following official, recognized, or institutional requirements, guidelines, recommendations, protocols, pathways, or other standards.

Year introduced: 1998

Test for cell-mediated antitumor immunity and related serum blocking factors based on the finding that leukocytes from cancer patients, but not from controls, when mixed in vitro with antigenic extracts of tumors of the same histological type, undergo a diminution in their normal adherence to glass surfaces. Sera from tumor-bearing patients block the LAI reaction of their own leukocytes or those of other patients with the same type of tumor.

Year introduced: 1991(1977)

Extent to which the patient follows prescribed treatment such as keeping APPOINTMENTS AND SCHEDULES and MEDICATION ADHERENCE for desired therapeutic outcome. It implies active responsibility shared by patient and health care providers.

Year introduced: 2018

Voluntary cooperation of the patient in taking drugs or medicine as prescribed. This includes timing, dosage, and frequency.

Year introduced: 2009

A method for the detection of very small quantities of antibody in which the antigen-antibody-complement complex adheres to indicator cells, usually primate erythrocytes or nonprimate blood platelets. The reaction is dependent on the number of bound C3 molecules on the C3b receptor sites of the indicator cell.

Year introduced: 1973(1971)

Voluntary cooperation of the patient in following a prescribed regimen.

Year introduced: 1975

binds complement-opsonized immune complexes in non-human primates; similar but not identical to complement receptor type 1 (CR1) in humans

Date introduced: July 12, 1992

efa1 - EHEC factor for adherence; required for in vitro adhesion of enterohaemorrhagic Escherichia coli (EHEC) to epithelial cells; GenBank AF159462

Date introduced: March 10, 2000

Mycoplasma hominis, variable adherence-associated gene is a surface-exposed, membrane-associated protein involved in the attachment of the bacterium to host cells; amino acid sequence in first source; GenBank U56827

Date introduced: November 6, 1998

a protein from human cervical epithelial cell line that mediates adherence of pathogenic Neisseria to non-binding cells; has identity with N-terminal region of WWP2; amino acid sequence in first source

Date introduced: June 11, 1998

A thin protein film on the surface of DENTAL ENAMEL. It is widely believed to result from the selective adsorption of precursor proteins present in SALIVA onto tooth surfaces, and to reduce microbial adherence to the TEETH.

Year introduced: 2004

A class of cell surface leukotriene receptors with a preference for leukotriene B4. Leukotriene B4 receptor activation influences chemotaxis, chemokinesis, adherence, enzyme release, oxidative bursts, and degranulation in polymorphonuclear leukocytes. There are at least two subtypes of these receptors. Some actions are mediated through the inositol phosphate and diacylglycerol second messenger systems.

Year introduced: 1994

Instructions issued by a physician pertaining to the institution, continuation, or withdrawal of life support measures. The concept includes policies, laws, statutes, decisions, guidelines, and discussions that may affect the issuance of such orders.

Year introduced: 1991

Declarations by patients, made in advance of a situation in which they may be incompetent to decide about their own care, stating their treatment preferences or authorizing a third party to make decisions for them. (Bioethics Thesaurus)

Year introduced: 1991

Family of proteins associated with the capacity of LEUKOCYTES to adhere to each other and to certain substrata, e.g., the C3bi component of complement. Members of this family are the LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; (LFA-1), the MACROPHAGE-1 ANTIGEN; (Mac-1), and the INTEGRIN ALPHAXBETA2 or p150,95 leukocyte adhesion protein. They all share a common beta-subunit which is the CD18 antigen. All three of the above antigens are absent in inherited LEUKOCYTE-ADHESION DEFICIENCY SYNDROME, which is characterized by recurrent bacterial infections, impaired pus formation, and wound healing as well as abnormalities in a wide spectrum of adherence-dependent functions of granulocytes, monocytes, and lymphoid cells.

Year introduced: 1990

Substances used to cause adherence of tissue to tissue or tissue to non-tissue surfaces, as for prostheses.

Year introduced: 1965(1963)

The adherence and merging of cell membranes, intracellular membranes, or artificial membranes to each other or to viruses, parasites, or interstitial particles through a variety of chemical and physical processes.

Year introduced: 1982

The larger fragment generated from the cleavage of COMPLEMENT C3 by C3 CONVERTASE. It is a constituent of the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb), and COMPLEMENT C5 CONVERTASES in both the classical (C4b2a3b) and the alternative (C3bBb3b) pathway. C3b participates in IMMUNE ADHERENCE REACTION and enhances PHAGOCYTOSIS. It can be inactivated (iC3b) or cleaved by various proteases to yield fragments such as COMPLEMENT C3C; COMPLEMENT C3D; C3e; C3f; and C3g.

Year introduced: 2006 (1978)

Adherence of cells to surfaces or to other cells.

Year introduced: 1972(1970)